Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas

Biochimie

Volumn 94, Issue 2, 2012, Pages 487-493

  Burden, Roberta E ^a,b   Gormley, Julie A ^a   Kuehn, Diana ^a   Ward, Claire ^a   Kwok, Hang Fai ^a   Gazdoiu, Mihaela ^a   McClurg, Angela ^a   Jaquin, Thomas J ^a   Johnston, James A ^a,c   Scott, Christopher J ^b   Olwill, Shane A ^a  

^a FUSION ANTIBODIES LTD   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Angiogenesis; Cathepsin; Chemotherapy; Invasion

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; FSN 0503; IMMUNOGLOBULIN CLASS; IRINOTECAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METRONOMIC DRUG ADMINISTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CATHEPSINS; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; CYSTEINE PROTEINASE INHIBITORS; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84855828185     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2011.08.017     Document Type: Article

References (38)

1. O. Vasiljeva, T. Reinheckel, C. Peters, D. Turk, V. Turk, and B. Turk Emerging roles of cysteine cathepsins in disease and their potential as drug targets Curr. Pharm. Des. 13 2007 387 403 (Pubitemid 46477760)
2. M.M. Mohamed, and B.F. Sloane Cysteine cathepsins: multifunctional enzymes in cancer Nat. Rev. Cancer 6 2006 764 775 (Pubitemid 44450465)
3. D. Hanahan, and R.A.Weinberg The hallmarks of cancer Cell 100 2000 57 70 (Pubitemid 30046295)
4. V. Gocheva, W. Zeng, D. Ke, D. Klimstra, T. Reinheckel, C. Peters, D. Hanahan, and J.A. Joyce Distinct roles for cysteine cathepsin genes in multistage tumorigenesis Genes. Dev. 20 2006 543 556 (Pubitemid 43345321)
5. J. Dennemärker, T. Lohmüller, J. Mayerle, M. Tacke, M.M. Lerch, L.M. Coussens, C. Peters, and T. Reinheckel Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis Oncogene 29 2010 1611 1621
6. F. Qian, S.J. Chan, Q.M. Gong, A.S. Bajkowski, D.F. Steiner, and A. Frankfater The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumours Biomed. Biochim. Acta 50 1991 531 540
7. T.Y. Nakagawa, W.H. Brissette, P.D. Lira, R.J. Griffiths, N. Petrushova, J. Stock, J.D. McNeish, S.E. Eastman, E.D. Howard, S.R. Clarke, E.F. Rosloniec, E.A. Elliott, and A.Y. Rudensky Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice Immunity 10 1999 207 217 (Pubitemid 29115626)
8. G.P. Shi, J.S. Munger, J.P. Meara, D.H. Rich, and H.A. Chapman Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease J. Biol. Chem. 267 1992 7258 7262
9. D. Brömme, P.R. Bonneau, P. Lachance, B. Wiederanders, H. Kirschke, C. Peters, D.Y. Thomas, A.C. Storer, and T. Vernet Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme J. Biol. Chem. 268 1993 4832 4838 (Pubitemid 23081601)
10. J.P. Liuzzo, S.S. Petanceska, D. Moscatelli, and L.A. Devi Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions Mol. Med. 5 1999 320 333 (Pubitemid 29342967)
11. T. Flannery, S. McQuaid, C. McGoohan, R.S. McConnell, G. McGregor, M. Mirakhur, P. Hamilton, J. Diamond, G. Cran, B. Walker, C. Scott, L. Martin, D. Ellison, C. Patel, C. Nicholson, D. Mendelow, D. McCormick, and P.G. Johnston Cathepsin S expression: an independent prognostic factor in glioblastoma tumours-a pilot study Int. J. Cancer 119 2006 854 860 (Pubitemid 44051449)
12. T. Flannery, R.S. McConnell, S. McQuaid, G. McGregor, M. Mirakhur, L. Martin, C. Scott, R. Burden, B. Walker, C. McGoohan, and P.G. Johnston Detection of cathepsin S cysteine protease in human brain tumour microdialysates in vivo Br. J. Neurosurg. 21 2007 204 209 (Pubitemid 46572895)
13. P.L. Fernández, X. Farré, A. Nadal, E. Fernández, N. Peiró, B.F. Sloane, G.P. Shi, H.A. Chapman, E. Campo, and A. Cardesa Expression of cathepsins B and S in the progression of prostate carcinoma Int. J. Cancer 95 2001 51 55
14. C. Lindahl, M. Simonsson, A. Bergh, E. Thysell, H. Antti, M. Sund, and P. Wikström Increased levels of macrophage-secreted cathepsin S during prostate cancer progression in TRAMP mice and patients Cancer Genomics Proteomics 6 2009 149 159
15. J. Kos, A. Sekirnik, G. Kopitar, N. Cimerman, K. Kayser, A. Stremmer, W. Fiehn, and B. Werle Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis Br. J. Cancer 85 2001 1193 1200 (Pubitemid 33052320)
16. R.E. Burden, J.A. Gormley, T.J. Jaquin, D.M. Small, D.J. Quinn, S.M. Hegarty, C. Ward, B. Walker, J.A. Johnston, S.A. Olwill, and C.J. Scott Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis Clin. Can. Res. 15 2009 6042 6051
17. G.P. Shi, G.K. Sukhova, M. Kuzuya, Q. Ye, J. Du, Y. Zhang, J.H. Pan, M.L. Lu, X.W. Cheng, A. Iguchi, S. Perrey, A.M. Lee, H.A. Chapman, and P. Libby Deficiency of the cysteine protease cathepsin S impairs microvessel growth Circ. Res. 92 2003 493 500 (Pubitemid 36368661)
18. B. Wang, J. Sun, S. Kitamoto, M. Yang, A. Grubb, H.A. Chapman, R. Kalluri, and G.P. Shi Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors J. Biol. Chem. 281 2006 6020 6029 (Pubitemid 43847703)
19. R.T. Poon, I.O. Ng, C. Lau, W.C. Yu, Z.F. Yang, S.T. Fan, and J. Wong Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study J. Clin. Oncol. 20 2002 1775 1785 (Pubitemid 34273266)
20. J. Hasan, R. Byers, and G.C. Jayson Intra-tumoural microvessel density in human solid tumours Br. J. Cancer 86 2002 1566 1577 (Pubitemid 34628110)
21. G.M. Tozer Measuring tumour vascular response to antivascular and antiangiogenic drugs Br. J. Radiol. 76 2003 S23 S35
22. G. Pueyo, R. Mesia, A. Figueras, A. Lozano, M. Baro, S. Vazquez, G. Capella, and J. Balart Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy Oncologist 15 2010 976 986
23. G. Bocci, A. Falcone, A. Fioravanti, P. Orlandi, A. Di Paolo, G. Fanelli, P. Viacava, A.G. Naccarato, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Allegrini Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib Br. J. Cancer 98 2008 1619 1629 (Pubitemid 351684682)
24. R.S. Kerbel, and B.A. Kamen The anti-angiogenic basis of metronomic chemotherapy Nat. Rev. Cancer 4 2004 423 436 (Pubitemid 38745528)
25. B. Laquente, F. Viñals, and J.R. Germ Metronomic chemotherapy: an antiangiogenic scheduling Clin. Transl. Oncol. 9 2007 93 98
26. A. Fioravanti, B. Canu, G. Al, P. Orlandi, G. Allegrini, T. Di Desidero, U. Emmenegger, G. Fontanini, R. Danesi, M. Del Tacca, A. Falcone, and G. Bocci Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer Eur. J. Pharmacol. 619 2009 8 14
27. H.J. Lee, Y.J. Lee, C.M. Kang, S. Bae, D. Jeoung, J.J. Jang, S.S. Lee, C.K. Cho, and Y.S. Lee Differential gene signatures in rat mammary tumors induced by DMBA and those induced by fractionated gamma radiation Radiat. Res. 170 2008 579 590
28. H.R. Seo, S. Bae, and Y.S. Lee Radiation-induced cathepsin S is involved in radioresistance Int. J. Cancer 124 2009 1794 1801
29. G. Allegrini, A. Falcone, A. Fioravanti, M.T. Barletta, P. Orlandi, F. Loupakis, E. Cerri, G. Masi, A. Di Paolo, R.S. Kerbel, R. Danesi, M. Del Tacca, and G. Bocci A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients Br. J. Cancer 98 2008 1312 1319 (Pubitemid 351543577)
30. J.A. Joyce, A. Baruch, K. Chehade, N. Meyer-Morse, E. Giraudo, F.Y. Tsai, D.C. Greenbaum, J.H. Hager, M. Bogyo, and D. Hanahan Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis Cancer Cell. 5 2004 443 453 (Pubitemid 38610246)
31. K.M. Bell-McGuinn, A.L. Garfall, M. Bogyo, D. Hanahan, and J.A. Joyce Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer Cancer Res. 67 2007 7378 7385 (Pubitemid 47206568)
32. U. Schurigt, L. Sevenich, C. Vannier, M. Gajda, A. Schwinde, F. Werner, A. Stahl, D. von Elverfeldt, A.K. Becker, M. Bogyo, C. Peters, and T. Reinheckel Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model Biol. Chem. 389 2008 1067 1074
33. C. Ward, D. Kuehn, R.E. Burden, J.A. Gormley, T.J. Jaquin, M. Gazdoiu, D. Small, R. Bicknell, J.A. Johnston, C.J. Scott, and S.A. Olwill Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF PLoS One 5 2010 e12543
34. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
35. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, and F. Kabbinavar Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N. Engl. J. Med. 350 2004 2335 2342 (Pubitemid 38702844)
36. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, A. Dowlati, R. Lilenbaum, and D.H. Johnson Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N. Engl. J. Med. 355 2006 2542 2550 (Pubitemid 44917502)
37. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
38. M. Pez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, F. Viñals, M. Inoue, G. Bergers, D. Hanahan, and O. Casanovas Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell. 15 2009 220 231